Publications by authors named "John T Rathbun"
Anti-glutamic acid decarboxylase (anti-GAD) antibodies are linked with both autoimmune diabetes and the rare neurological disorder stiff person syndrome (SPS). SPS is an uncommon autoimmune-mediated condition characterized by painful episodic spasms and progressive muscle rigidity. We present the case of a 23-year-old non-diabetic, insulin-naïve woman with known SPS who was hospitalized for SPS-related symptomatology.
View Article and Find Full Text PDFArticle Synopsis
- Radium-223 (Xofigo) improves overall survival for men with metastatic castrate-resistant prostate cancer (mCRPC) but there's limited data from community practice, especially regarding its use alongside abiraterone and enzalutamide.
- A retrospective study involving 35 men with mCRPC showed that median overall survival was 10 months, with factors like lower pain levels and better Eastern Cooperative Oncology Group Performance Status (ECOG PS) linked to longer survival.
- The study found that radium-223 was well tolerated, and combining it with abiraterone or enzalutamide did not increase toxicity, suggesting that early and aggressive treatment with radium-223 could be beneficial
Although radical prostatectomy is a popular treatment modality for clinically localized prostate cancer, 10-year biochemical recurrence can reach 28%. Before salvage radiation therapy (SRT), prostate-specific antigen (PSA) values alone should be used cautiously in predicting SRT eligibility. A long, slow PSA rise may suggest locally confined disease still amenable to SRT; corresponding imaging to identify potential gross recurrence is useful.
View Article and Find Full Text PDFAim: To present our experience comparing cisplatin- and cetuximab-based radiotherapy for locally-advanced head and neck squamous cell carcinoma.
Background: The comparative effectiveness of cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradiotherapy (BRT) for locally-advanced head and neck squamous cell carcinoma (LAHNSCC) continues to be explored.
Materials And Methods: Outcomes of LAHNSCC patients treated with CRT (125) or BRT (34) at two institutions were compared retrospectively, with attention to overall survival (OS), cancer-specific survival (CSS), locoregional control (LRC), and distant control (DC).